A recently published phase II performed by Chang et al studied the same regimen but with a lower docetaxel dose (75 mg/m2) and without G-CSF support. Seventy-three patients were treated for 4 cycles (11 of them were TNBC). Patients HER2 positive were additionally randomized to chemotherapy alone or in combination with trastuzumab weekly. Seventy-one patients underwent surgery from which 19 (26.8%) had pCR (absence of invasive breast cancer in the breast), 6 of them within the TNBC subgroup. Grade 3/4 toxicities other than hematological, such as neutropenia (43%), and febrile neutropenia (4%) were rare. Grade 3 docetaxel hypersensitivity was noted in 4% of patients and all other grade 3/4 adverse events occurred in less than 2% of them.